S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%

NYSE · JNJ

Johnson & Johnson

Healthcare · Drug Manufacturers - General

$273.20

Down-$2.00 (-0.73%)

Updated Oct 31, 2026, 10:25 AM

SID Score

8.1/10

Composite research score

Smart Money

50/100

Neutral

Market cap: 505.78B
P/E ratio: 20.3
Dividend yield: 1.88%
52-week range: $203.85 – $281.07
Volume: 8.97M
Avg. volume: 8.82M

Price performance · JNJ

JNJ price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

Last close: $273.20
Period change: +6.71%
Period low: $248.61
Period high: $275.20

Daily close

View OHLC price history

JNJ OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Oct 30, 2026	$280.00	$282.015	$273.13	$273.20	8.97M
Oct 29, 2026	$275.31	$278.05	$273.595	$275.20	6.02M
Oct 28, 2026	$265.83	$272.75	$264.20	$271.04	6.4M
Oct 27, 2026	$265.25	$269.09	$264.83	$268.73	5.77M
Oct 26, 2026	$266.74	$272.36	$264.97	$266.30	5.78M
Oct 23, 2026	$265.82	$266.025	$262.40	$263.81	5.31M
Oct 22, 2026	$260.54	$269.67	$259.04	$267.61	10.13M
Oct 21, 2026	$257.50	$257.80	$254.56	$257.78	6.56M
Oct 20, 2026	$257.48	$260.77	$256.422	$259.36	7.66M
Oct 19, 2026	$254.43	$255.56	$251.50	$253.79	8.85M
Oct 16, 2026	$255.52	$257.55	$254.00	$255.56	6.55M
Oct 15, 2026	$257.11	$262.445	$252.62	$253.28	9.28M
Oct 14, 2026	$249.095	$253.94	$248.50	$253.91	9.66M
Oct 13, 2026	$254.56	$256.1822	$245.17	$248.61	16.65M
Oct 12, 2026	$261.60	$264.39	$260.3685	$263.73	5.91M
Oct 9, 2026	$255.09	$261.61	$254.985	$261.44	5.73M
Oct 8, 2026	$256.22	$257.80	$251.945	$256.48	6.18M
Oct 7, 2026	$256.21	$260.68	$255.73	$258.45	5.41M
Oct 6, 2026	$254.15	$255.48	$251.17	$254.78	5.66M
Oct 5, 2026	$256.00	$256.24	$252.51	$252.93	10.03M
Oct 2, 2026	$259.38	$259.38	$255.12	$256.03	10.94M

Latest JNJ news

The latest Smart Investors Daily articles mentioning JNJ.

Featured By

Inc.

Nasdaq

SID Score: 7.1/10
Fair value: $285.95
Generated: Oct 25, 2026
Model: claude-haiku-4-5-20251001

Executive Summary

Johnson & Johnson is trading at $263.81 with a market capitalization of $505.8 billion, presenting an 8.4% upside to the fair value estimate of $285.95. The company demonstrates solid operational performance with a moderate SID score of 7.1/10, supported by strong growth prospects (Grade A) and reliable dividend payments (Grade B). However, the valuation appears stretched with a P/E ratio of 20.3x, and conflicting signals from analyst consensus create uncertainty about near-term price targets.

Fundamental Analysis

JNJ has consistently beaten earnings estimates across recent quarters, with Q3 2026 EPS of $2.59 versus $2.53 estimated, continuing a positive trend through 2026. The company's profitability grade of C suggests room for improvement in operational efficiency despite solid top-line performance, while the D rating in Value indicates the stock may not offer compelling value at current levels relative to fundamentals. The 0.02% dividend yield appears unusually low for a defensive healthcare dividend aristocrat, warranting investigation into whether this reflects data anomalies or significant capital allocation strategy changes.

Technical Analysis

The stock is trading above both its 50-day moving average ($265.2) and 200-day moving average ($247.78), indicating a sustained uptrend with approximately 6.5% appreciation above the 200-day support level. The RSI(14) of 59.0 suggests the stock is neither overbought nor oversold, providing room for additional upside movement without technical exhaustion. The current price positioning within established technical support levels supports the upside potential to the $285.95 fair value estimate.

Analyst & Insider Sentiment

Insider buying activity in early September 2026 by three separate executives (Woods, Pinto, and Hewson purchasing between 113-181 shares each) signals confidence in company fundamentals at current levels. Conversely, Timothy Schmid's significant sell activity (33,597 shares sold on September 2) represents a notable contradiction that may reflect option-related transactions or portfolio rebalancing rather than fundamental concerns. The analyst consensus rating of "Buy" with an average price target of $207.08 creates a confusing contradiction, as this target is 21.5% below current market price and suggests potential downside risk.

Risk Assessment

The primary concern is the significant disconnect between the fair value estimate ($285.95) and the average analyst price target ($207.08), creating substantial valuation uncertainty and suggesting analysts may be more cautious than quantitative models indicate. The mediocre profitability grade (C) and weak value grade (D) indicate underlying concerns about earnings quality and valuation sustainability, particularly given the elevated 20.3x P/E multiple. Healthcare sector risks including regulatory pressures, patent expirations, and clinical trial outcomes present structural headwinds that may justify analyst skepticism despite recent earnings beats.

Investment Thesis

Johnson & Johnson represents a quality defensive healthcare position with demonstrable earnings resilience and strong growth prospects, supported by insider confidence and technical strength suggesting near-term upside to $285.95. However, investors should exercise caution given the conflicting analyst price target of $207.08 and moderate valuation metrics that offer limited margin of safety at current prices. The investment case is most compelling for long-term holders seeking healthcare exposure with dividend income, though the 0.02% yield suggests this is primarily a capital appreciation play rather than an income investment.